Image Place holder

Sarah Hoffe, MD


Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Sarah Hoffe is the Section Head of GI Radiation Oncology at Moffitt Cancer Center and joined the faculty in 2006. She is an Associate Member at Moffitt and Associate Professor in the University Of South Florida Morsani College Of Medicine’s Department of Oncologic Sciences.    Dr. Hoffe’s research and clinical interests include cancers of the esophagus, stomach, liver, pancreas, bile duct, rectum, colon, anus, as well as neuroendocrine cancers. She has experience with advanced radiation therapy techniques such as intensity modulated radiation therapy (IMRT), three dimensional conformal radiation therapy (3D-CRT), stereotactic body radiation therapy (SBRT), radioembolization, and image guided radiation therapy (IGRT) using endoscopically implanted fiducial markers. At Moffitt, she works closely with her multidisciplinary colleagues including GI surgeons, medical oncologists, gastroenterologists, radiologists and pathologists to develop new treatments for patients with GI cancers. She is very interested in 4D PET/CT imaging and works with the PET/CT committee at Moffitt  In addition to GI cancers and radiation oncology, Dr. Hoffe is also interested in the integration of novel patient engagement technologies that will improve the patient experience, such as piloting novel virtual reality tools.    After completing her undergraduate studies at Brown University, Dr. Hoffe received her MD degree from the University of Vermont.  She then completed a transitional year internship at Mayo Clinic Jacksonville followed by residency in radiation oncology at Duke University Medical Center and Memorial Sloan-Kettering Cancer Center and fellowship at MD Anderson Cancer Center.   Dr. Hoffe devotes a significant portion of her time to the promotion of medical education. Nationally, she is the Director of eContouring at ASTRO, is on the advisory board for the Contemporary Radiation Oncology Journal, and is a contributor to the Up to Date Online educational site, having co-authored the section on bone metastases. She serves on the ASTRO Education Committee and the HIMSS connected patient committee. Locally, she is on the Editorial Board of Cancer Control Journal and is active at the USF Morsani College of Medicine where she is a coach for the SELECT program and the leadership competency co-director.     In 2009, Dr. Hoffe was the first radiation oncologist at Moffitt to be selected as the Physician of the Year.

Education & Training

Board Certification:

  • Radiation Oncology

Fellowship:

  • University of Texas MD Anderson Cancer Center - Radiation Oncology

Residency:

  • Duke University Medical Center - Radiation Oncology
  • Memorial Sloan Kettering Cancer Center - Radiation Oncology

Medical School:

  • University of Vermont - MD
Participating Trials

CLINICAL TRIAL 18941
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Condition: Gastrointestinal Tumor
Intervention: FOLFIRINOX; FOLFOX
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 2017 Oct;24(5). Pubmedid: 28975822.
  • Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar;56(3):391-397. Pubmedid: 27885876.
  • Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open. 2017 Jun;5(6):E496-E504. Pubmedid: 28573183. Pmcid: PMC5451282.
  • Venkat PS, Hoffe SE, Frakes JM. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul;24(3). Pubmedid: 28975831.
  • Salem AI, Thau MR, Strom TJ, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL. Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center. Dis Esophagus. 2017 Jan;30(1):1-7. Pubmedid: 27149640.
  • Zhang DG, Feygelman V, Moros EG, Latifi K, Hoffe S, Frakes J, Zhang GG. Superficial and peripheral dose in compensator-based FFF beam IMRT. J Appl Clin Med Phys. 2017 Jan;18(1):151-156. Pubmedid: 28291940.
  • Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017 Feb;28(2):254-259. Pubmedid: 27955832.
  • Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2017 Aug. Pubmedid: 28833197.
  • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E195. Pubmedid: 27674030.
  • Mellon EA, Hoffe SE, Frakes JM, Strom T, Springett GM, Shridhar R, Centeno BA, Malafa MP, Chuong MD, Hodul PJ. Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E165. Pubmedid: 27673949.
  • Pearson AL, Jin W, Mellon EA, Frakes JM, Strom T, Springett GM, Kim R, Mahipal A, Hodul PJ, Pimiento JM, Shridhar R, Malafa MP, Hoffe SE. Post-Stereotactic Body Radiation Therapy (SBRT) Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With Borderline Resectable Pancreatic Cancer (BRPC) May Be a Prognostic Biomarker. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E153. Pubmedid: 27673917.
  • Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. Cancer Control. 2016 Oct;23(4):446-454. Pubmedid: 27842335.
  • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E194-E195.
  • Dhadham GC, Hoffe S, Harris CL, Klapman JB. Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility. Endosc Int Open. 2016 Mar;4(3):E378-E382. Pubmedid: 27004258. Pmcid: PMC4798935.
  • Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol. 2016 Jun;7(3):387-394. Pubmedid: 27284471. Pmcid: PMC4880760.
  • Kucera S, Barthel J, Klapman J, Shridhar R, Hoffe S, Harris C, Almhanna K, Meredith K. Small caliber covered self-expanding metal stents in the management of malignant dysphagia. J Gastrointest Oncol. 2016 Jun;7(3):411-419. Pubmedid: 27284474. Pmcid: PMC4880758.
  • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Jan;25(1):51-62. Pubmedid: 26560877.
  • Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2016 Jan. Pubmedid: 26796313.
  • Srikumar T, Markow M, Centeno B, Hoffe S, Tao J, Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb;23(1):e70-e74. Pubmedid: 26966416. Pmcid: PMC4754072.
  • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb;118(2):382-386. Pubmedid: 26861740.
  • Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative . Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016 Dec;7(52):85785-85797. Pubmedid: 27589689. Pmcid: PMC5349874.
  • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec;22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
  • Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Aug;95(5):1399-1404. Pubmedid: 27319288.
  • Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016 Aug;7(4):562-569. Pubmedid: 27563446. Pmcid: PMC4963374.
  • Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2016 Apr;23(4):1371-1379. Pubmedid: 26661409.
  • Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL. Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy. J Gastrointest Oncol. 2016 Apr;7(2):206-212. Pubmedid: 27034787. Pmcid: PMC4783744.
  • Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol. 2016 Apr;7(2):158-165. Pubmedid: 27034781. Pmcid: PMC4783740.
  • Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer. 2015 Sep;46(3):284-290. Pubmedid: 26018826.
  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep;14(3):146-153. Pubmedid: 25795047.
  • Balducci L, Dolan D, Hoffe SA. Palliative Care in Older Patients With Cancer. Cancer Control. 2015 Oct;22(4):480-488. Pubmedid: 26678975.
  • Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol. 2015 Oct;117(1):159-164. Pubmedid: 26235848.
  • Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J, Hodul P, Malafa MP, Shridhar R. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc. 2015 Nov;29(11):3273-3281. Pubmedid: 25631110. Pmcid: PMC4918460.
  • Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R, Almhanna K. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015 Nov;28(8):782-787. Pubmedid: 25155802.
  • Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015 Nov;112(6):597-602. Pubmedid: 26394724.
  • Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. Geriatr Oncol. 2015 Mar;6(2):127-132. Pubmedid: 25555451.
  • Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys. 2015 Jul;92(4):837-842. Pubmedid: 25838188. Pmcid: PMC4481172.
  • Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-985. Pubmedid: 25734581.
  • Almhanna K, Hoffe S. Esophageal cancer 2015, more questions than answers. J Gastrointest Oncol. 2015 Feb;6(1):1-2. Pubmedid: 25642332. Pmcid: PMC4294825.
  • Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol. 2015 Feb;6(1):31-38. Pubmedid: 25642335. Pmcid: PMC4294822.
  • Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist. 2015 Feb;20(2):134-142. Pubmedid: 25561508. Pmcid: PMC4319638.
  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb;6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.
  • Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol. 2015 Dec. Pubmedid: 26703814.
  • Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2014 Sep;18(9):1013-1021. Pubmedid: 23966224. Pmcid: PMC3780633.
  • Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange JL, Markouizou A, Pfeffer R, Villa S. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014 Nov;25(11):2134-2146. Pubmedid: 24625455.
  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014 Nov;21(12):3744-3750. Pubmedid: 24854492.
  • Chuong MD, Fernandez DC, Shridhar R, Hoffe SE, Saini A, Hunt D, Meredith KL, Biagioli MC. High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients. Brachytherapy. 2014 May;12(5):457-462. Pubmedid: 23707855.
  • Latifi K, Dilling TJ, Hoffe SE, Stevens CW, Moros EG, Zhang GG. Evaluating Effects of Radiation Therapy Treatment on 4DCT-Calculated Lung Ventilation. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S6-S7. Pubmedid: 24674563.
  • Saeed N, Latifi K, Hoffe SE, Cruz A, Opp DW, Moros EG, Zhang GG, Budzevich MM, Shridhar R, Dilling TJ. Optimizing Options for Re-irradiation With Deformable Image Registration of Prior Plans. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S16-S17. Pubmedid: 24674497.
  • Fernandez DC, Hoffe SE, Barthel JS, Vignesh S, Klapman JB, Harris C, Almhanna K, Biagioli MC, Meredith KL, Feygelman V, Rao NG, Shridhar R. Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol. 2014 Mar;3(1):32-39. Pubmedid: 24674261.
  • Budzevich MM, Kuykendall CC, Latifi K, Oliver J, Dilling TJ, Hoffe SE, Eikman EA, Montilla-Soler JI, Zhang GG, Moros EG. A Method to Determine the Optimal Number of Bins in 4D PET. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S25. Pubmedid: 24674527.
  • Figura N, Latifi K, Dilling TJ, Kuykendall CC, Eikman EA, Moros EG, Zhang GG, Leuthold S, Mehra C, Hoffe SE. Dosimetric Implications of Treating 4D PET/CT-Defined Maximum Inhale Versus Exhale Target Volumes in Esophageal Cancer. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S34-S35. Pubmedid: 24674556.
  • Oliver JA, Budzevich M, Zhang G, Moros EG, Latifi K, Kuykendall C, Hoffe S, Montilla-Soler J, Eikman E, Dilling T. Positron emission tomography texture analysis of necrosis in primary adenocarcinomas of the lung. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S29-S30. Pubmedid: 24674537.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg. 2014 Mar;18(3):505-511. Pubmedid: 24443204.
  • Kuykendall CC, Budzevich MM, Latifi K, Moros EG, Hoffe SE, Dilling TJ, Zhang GG, Montilla-Soler JL, Eikman EA. 4D PET/CT: Radiology Imaging to Radiation Therapy. Pract Radiat Oncol. 2014 Mar;3(2 Suppl 1):S28. Pubmedid: 24674534.
  • Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug;57(8):941-957. Pubmedid: 25003289. Pmcid: PMC4100249.
  • Hoffe S, Rao N, Shridhar R. Neoadjuvant vs Adjuvant Therapy for Resectable Pancreatic Cancer: The Evolving Role of Radiation. Semin Radiat Oncol. 2014 Apr;24(2):113-125. Pubmedid: 24635868.
  • Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014 Apr;120(8):1171-1177. Pubmedid: 24390779.
  • Ashraf N, Hoffe S, Kim R. French FNCLCC/FFCD 9703 study. Oncologist. 2014 Apr;19(4):431. Pubmedid: 24729607. Pmcid: PMC3983828.
  • de la Fuente SG, Weber J, Hoffe SE, Shridhar R, Karl R, Meredith KL. Initial experience from a large referral center with robotic-assisted Ivor Lewis esophagogastrectomy for oncologic purposes. Surg Endosc. 2013 Apr;27(9):3339-3347. Pubmedid: 23549761.
  • Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013 Sep;20(9):3038-3043. Pubmedid: 23625142.
  • Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith KL. Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013 Sep;17(9):1562-1568. Pubmedid: 23818125.
  • Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Jun;119(9):1636-1642. Pubmedid: 23361968.
  • Melis M, Weber J, Shridhar R, Hoffe S, Almhanna K, Karl RC, Meredith KL. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open. 2013 May;3(5). Pubmedid: 23645908. Pmcid: PMC3646172.
  • Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013 Mar;31(7):886-894. Pubmedid: 23341531. Pmcid: PMC4820756.
  • Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, Dinwoodie W, Rao N, Meredith KL, Shridhar R. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res. 2013 Mar;6(2):39-45. Pubmedid: 23745158. Pmcid: PMC3674462.
  • Latifi K, Forster KM, Hoffe SE, Dilling TJ, Dekker A, Van Elmpt W, Zhang GG. Dependence of ventilation image derived from 4D CT on deformable image registration and ventilation algorithms. J Appl Clin Med Phys. 2013 Jul;14(4):4247. Pubmedid: 23835389.
  • Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul;86(3):516-522. Pubmedid: 23562768.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Prognostic impact of lymph node retrieval and ratio in gastric cancer: a U.S. single center experience. J Gastrointest Surg. 2013 Dec;17(12):2059-2066. Pubmedid: 24129828.
  • Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. J Gastrointest Surg. 2013 Aug;17(8):1339-1345. Pubmedid: 23749498.
  • Hernandez JM, Dimou F, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith K. Defining the learning curve for robotic-assisted esophagogastrectomy. J Gastrointest Surg. 2013 Aug;17(8):1346-1351. Pubmedid: 23690208.
  • Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013 Aug;20(8):2706-2712. Pubmedid: 23504118.
  • Vignesh S, Hoffe SE, Meredith KL, Shridhar R, Almhanna K, Gupta AK. Endoscopic Therapy of Neoplasia Related to Barrett's Esophagus and Endoscopic Palliation of Esophageal Cancer. Cancer Control. 2013 Apr;20(2):117-129. Pubmedid: 23571702.
  • Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013 Apr;20(2):111-116. Pubmedid: 23571701.
  • Wong JY, Shridhar R, Almhanna K, Hoffe SE, Karl RC, Meredith KL. The impact of body mass index on esophageal cancer. Cancer Control. 2013 Apr;20(2):138-143. Pubmedid: 23571704.
  • Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control. 2013 Apr;20(2):97-110. Pubmedid: 23571700.
  • Javedan K, Zhang GG, Hoffe S, Feygelman V, Forster K. Comparing dose in the build-up region between compensator- and MLC-based IMRT. J Appl Clin Med Phys. 2012 Sep;13(5):3748. Pubmedid: 22955641.
  • Gwede CK, Vadaparampil ST, Hoffe S, Quinn GP. The role of radiation oncologists and discussion of fertility preservation in young cancer patients. Pract Radiat Oncol. 2012 Oct;2(4):242-247. Pubmedid: 24674159.
  • Mathew BM, Daas AY, Centeno BA, Hoffe S, Valone T, Patel M, Springett GM. Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma. Clin Adv Hematol Oncol. 2012 May;10(5):340-343. Pubmedid: 22706548.
  • Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL. Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Ann Surg Oncol. 2012 May;19(5):1678-1684. Pubmedid: 22045465.
  • Shridhar R, Dombi GW, Weber J, Hoffe SE, Meredith K, Konski A. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol. 2012 Jun;35(3):216-221. Pubmedid: 21378540.
  • Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg. 2012 Jul;16(7):1296-1302. Pubmedid: 22399271.
  • Robinson J, Opp D, Zhang G, Cashon K, Kozelka J, Hunt D, Walker L, Hoffe S, Shridhar R, Feygelman V. Evaluating dosimetric accuracy of flattening filter free compensator-based IMRT: measurements with diode arrays. Med Phys. 2012 Jan;39(1):342-352. Pubmedid: 22225304.
  • Hoffe S, Balducci L. Cancer and age: general considerations. Clin Geriatr Med. 2012 Feb;28(1):1-18. Pubmedid: 22326032.
  • Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2012 Apr;2011:439752. Pubmedid: 22162711. Pmcid: PMC3227385.
  • Shridhar R, Dombi GW, Finkelstein SE, Meredith KL, Hoffe SE. Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2011 Sep;117(17):3908-3916. Pubmedid: 21365627.
  • Vignesh S, Hoffe SE, Saif MW. EUS-guided pancreatic diagnosis and beyond. Highlights from the "2011 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. January 20-22, 2011. JOP. 2011 Mar;12(2):86-91. Pubmedid: 21386627.
  • Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, Shridhar R, Turaga KK, Dittrick G, Dean EM, Karl RC, Meredith KL. An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2011 Mar;18(3):824-831. Pubmedid: 20865331. Pmcid: PMC4623586.
  • Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res. 2011 Jul;4(4):128-134. Pubmedid: 22368736. Pmcid: PMC3283109.
  • Barthel JS, Kucera S, Harris C, Canchi D, Hoffe S, Meredith K. Cryoablation of persistent Barrett's epithelium after definitive chemoradiation therapy for esophageal adenocarcinoma. Gastrointest Endosc. 2011 Jul;74(1):51-57. Pubmedid: 21549371.
  • Zhang G, Feygelman V, Stevens C, Li W, Leuthold S, Springett G, Hoffe S. Re-planning for compensator-based IMRT with original compensators. Med Dosim. 2011 Feb;36(1):102-108. Pubmedid: 20207532.
  • Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011 Aug;104(2):155-161. Pubmedid: 21520097. Pmcid: PMC3347705.
  • McLean K, Lilienfeld H, Caracciolo JT, Hoffe S, Tourtelot JB, Carter WB. [In Process Citation]. Cancer Control. 2011 Apr;18(2):113-126. Pubmedid: 21451454.
  • Biagioli MC, Hoffe SE. Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control. 2010 Oct;17(4):223-232. Pubmedid: 20861810.
  • Hoffe SE, Shridhar R, Biagioli MC. Radiation therapy for rectal cancer: current status and future directions. Cancer Control. 2010 Jan;17(1):25-34. Pubmedid: 20010516.
  • Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control. 2010 Jan;17(1):44-51. Pubmedid: 20010518.
  • Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. Gastrointest Endosc. 2010 Feb;71(2):235-240. Pubmedid: 20003971.
  • Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control. 2010 Apr;17(1):100-110. Pubmedid: 20404793.
  • Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010 Apr;17(4):1159-1167. Pubmedid: 20140529.
  • Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008 Oct;15(4):295-307. Pubmedid: 18813197.
  • Dilling TJ, Hoffe SE. Stereotactic body radiation therapy: transcending the conventional to improve outcomes. Cancer Control. 2008 Apr;15(2):104-111. Pubmedid: 18376377.
  • Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007 Sep;85(4):216-220. Pubmedid: 17541257.
  • Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report. J Med Case Rep. 2007;1:95. Pubmedid: 17880715. Pmcid: PMC2040153.